Compared with small molecules and conventionally selected antibodies, epitope-selective antibodies exhibit precise target selectivity that confers enhanced safety and pharmacodynamic properties.

It is possible to substantially enhance these antibodies’ therapeutic potential via humanization, effectively reducing ...

Kumamoto University researchers have identified a powerful antibody that can neutralize a wide range of SARS-CoV-2 variants, ...

This article is based on a poster originally authored by Sophie Snow, Kira Freeman, Zaynab Isseljee, Alice Brankin and Christine Sanfelice, which was presented at ELRIG Drug Discovery 2024 in ...

AK0610 is engineered from an antibody isolated from a recovered infant and targets the pre-fusion F protein of RSV. It has a ...

OmniAb, Inc. (NASDAQ: OABI) today announced that two presentations featuring the Company's technologies were delivered at the 2024 Antibody Engineering & Therapeutics Conference (AETC) underway in San ...

Transcenta Holding Limited, announced late-breaking presentation of preclinical study results of novel humanized LIV-1 ...

Absci has achieved a breakthrough by de novo designing an antibody that targets a previously difficult-to-drug epitope in the HIV “caldera” region. This breakthrough potentially aids the development ...

Researchers from Exelixis Inc. described the preclinical characterization of XB-002, an antibody-drug conjugate consisting of a monoclonal antibody recognizing a tissue factor (TF) epitope that does ...